MedTrace Logo

Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy

NCT04370145 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-04-11

No results posted yet for this study

Summary

Application of multi-center, prospective study on the severity of postoperative cholangitis biliary atresia classification, according to the degree of cholangitis targeted therapy, to improve the therapeutic effect of postoperative cholangitis biliary atresia, decrease the overuse of antibiotics related complications.

Conditions

  • Cholangitis, Secondary Biliary
  • Treatment Compliance
  • Antibodies Drug Specific

Interventions

DRUG

Sulperazon

moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.

DRUG

Teicoplanin

severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.

DRUG

Meropenem Injection

cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.

Sponsors & Collaborators

  • Shanghai Children's Hospital

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Feng Jiexiong, Postdoctoral · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-10-01
Completion
2022-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370145 on ClinicalTrials.gov